1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Neurofibromatoses Type I (Von Recklinghausen’s Disease) Global Clinical Trials Review, H2, 2015

Neurofibromatoses Type I (Von Recklinghausen’s Disease) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Neurofibromatoses Type I (Von Recklinghausen’s Disease) Global Clinical Trials Review, H2, 2015" provides an overview of Neurofibromatoses Type I (Von Recklinghausen’s Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Neurofibromatoses Type I (Von Recklinghausen’s Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Neurofibromatoses Type I (Von Recklinghausen’s Disease) Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Neurofibromatoses Type I (Von Recklinghausen's Disease) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Clinical Trials by G7 Countries: Proportion of Neurofibromatoses Type I (Von Recklinghausen's Disease) to Genetic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Unaccomplished Trials of Neurofibromatoses Type I (Von Recklinghausen's Disease) 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials 26
Prominent Drugs 27
Clinical Trial Profiles 28
Clinical Trial Overview of Top Companies 28
AstraZeneca Plc 28
Clinical Trial Overview of AstraZeneca Plc 28
Novartis AG 29
Clinical Trial Overview of Novartis AG 29
ZonMw 30
Clinical Trial Overview of ZonMw 30
Sarcoma Alliance for Research through Collaboration 31
Clinical Trial Overview of Sarcoma Alliance for Research through Collaboration 31
Quintiles Transnational Holdings Inc. 32
Clinical Trial Overview of Quintiles Transnational Holdings Inc. 32
Pfizer Inc. 33
Clinical Trial Overview of Pfizer Inc. 33
Kolltan Pharmaceuticals, Inc. 34
Clinical Trial Overview of Kolltan Pharmaceuticals, Inc. 34
F. Hoffmann-La Roche Ltd. 35
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 35
Daiichi Sankyo Company, Limited 36
Clinical Trial Overview of Daiichi Sankyo Company, Limited 36
Array BioPharma Inc. 37
Clinical Trial Overview of Array BioPharma Inc. 37
Clinical Trial Overview of Top Institutes / Government 38
National Cancer Institute 38
Clinical Trial Overview of National Cancer Institute 38
University of Alabama at Birmingham 40
Clinical Trial Overview of University of Alabama at Birmingham 40
Massachusetts General Hospital 41
Clinical Trial Overview of Massachusetts General Hospital 41
Assistance Publique - Hopitaux de Paris 42
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 42
Central Manchester University Hospitals NHS Foundation Trust 43
Clinical Trial Overview of Central Manchester University Hospitals NHS Foundation Trust 43
Centre Hospitalier Universitaire de Nantes 44
Clinical Trial Overview of Centre Hospitalier Universitaire de Nantes 44
Erasmus MC 45
Clinical Trial Overview of Erasmus MC 45
Foundation IRCCS Neurological Institute Carlo Besta 46
Clinical Trial Overview of Foundation IRCCS Neurological Institute Carlo Besta 46
Hospices Civils de Lyon 47
Clinical Trial Overview of Hospices Civils de Lyon 47
Indiana University 48
Clinical Trial Overview of Indiana University 48
Five Key Clinical Profiles 49
Appendix 88
Abbreviations 88
Definitions 88
Research Methodology 89
Secondary Research 89
About GlobalData 90
Contact Us 90
Disclaimer 90
Source 91

List of Tables
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials by Region, 2015* 8
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 11
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 12
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, North America, Top Countries, 2015* 13
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 14
Proportion of Neurofibromatoses Type I (Von Recklinghausen's Disease) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015* 15
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials by Phase, 2015* 18
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 19
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 20
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 21
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Suspended Clinical Trials, 2015* 22
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 23
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 24
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 25
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 26
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 27
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca Plc, 2015* 28
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 29
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by ZonMw, 2015* 30
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sarcoma Alliance for Research through Collaboration, 2015* 31
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Quintiles Transnational Holdings Inc., 2015* 32
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 33
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Kolltan Pharmaceuticals, Inc., 2015* 34
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2015* 35
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2015* 36
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Array BioPharma Inc., 2015* 37
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 38
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Alabama at Birmingham, 2015* 40
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2015* 41
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2015* 42
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Central Manchester University Hospitals NHS Foundation Trust, 2015* 43
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Centre Hospitalier Universitaire de Nantes, 2015* 44
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2015* 45
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Foundation IRCCS Neurological Institute Carlo Besta, 2015* 46
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hospices Civils de Lyon, 2015* 47
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Indiana University, 2015* 48

List of Figures
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials by Region (%), 2015* 8
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 11
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 12
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 13
Proportion of Neurofibromatoses Type I (Von Recklinghausen's Disease) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015* 15
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 18
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 19
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 20
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 21
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 23
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 24
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 25
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 26
Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 27
GlobalData Methodology 89

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.